Canaccord analyst Edward Nash lowered the firm’s price target on Pliant Therapeutics to $43 from $48 and keeps a Buy rating on the shares. The firm updated its model following positive 12-week data in PSC from high dose bexotegrast (BEXO).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PLRX:
- Pliant Therapeutics price target lowered to $47 from $49 at Oppenheimer
- Pliant Therapeutics Achieves Success in Liver Disease Trial
- 3 Best Stocks to Buy Now, 2/6/2024, According to Top Analysts
- Pliant Therapeutics price target lowered to $48 from $52 at H.C. Wainwright
- Pliant Therapeutics announces data from INTEGRIS-PSC Phase 2a trial
